Trabectedin
Trabectedin (ecteinascidin-743, ET-743) is a marine-derived tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA, distorting the DNA helix, stalling RNA polymerase II, and triggering nucleotide excision repair machinery to generate lethal double-strand breaks preferentially in actively transcribed genes. It is approved for unresectable soft tissue sarcoma and relapsed ovarian cancer (in combination with pegylated liposomal doxorubicin), and is under investigation for other malignancies. Its unique mechanism of action in transcription-coupled repair makes it active in tumors with deficient homologous recombination.
Peso Molecular
761,8000 g/mol
LogP
3,40
TPSA
194,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4
InChI
InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
Molecular Formula
C39H43N3O11S
HBD / HBA
4 / 15
Ligações Rotacionáveis
4
Átomos Pesados
54
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Trabectedin (ecteinascidin-743, ET-743) is a marine-derived tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA, distorting the DNA helix, stalling RNA polymerase II, and triggering nucleotide excision repair machinery to generate lethal double-strand breaks preferentially in actively transcribed genes. It is approved for unresectable soft tissue sarcoma and relapsed ovarian cancer (in combination with pegylated liposomal doxorubicin), and is under investigation for other malignancies. Its unique mechanism of action in transcription-coupled repair makes it active in tumors with deficient …
Yes, Trabectedin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL450449. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 108150. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trabectedin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trabectedin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trabectedin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trabectedin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trabectedin"></drugfyi-drug>